Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
| Autor: | Jianzhong He, Daniel R. Gomez, Everett J. Moding, Rene F. Bonilla, Anne Tsao, Jacob J. Chabon, Ryan B. Ko, Ting Xu, Zhongxing Liao, Ash A. Alizadeh, Maximilian Diehn, Yawei Qiao, Steven H. Lin, Linda Gojenola, Yufei Liu, Kavitha Ramchandran, Aadel A. Chaudhuri, Joel W. Neal, Christopher H. Yoo, John V. Heymach, Millie Das, Carol D. Jones, Heather A. Wakelee, Barzin Y. Nabet, Sukhmani K. Padda, Billy W. Loo, Angela B. Hui |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Lung Neoplasms Neoplasm Residual medicine.medical_treatment Locally advanced Disease Article Circulating Tumor DNA Carcinoma Non-Small-Cell Lung hemic and lymphatic diseases Internal medicine medicine Humans Lung cancer Pneumonitis business.industry Immunotherapy medicine.disease Immune checkpoint Circulating tumor DNA Disease Progression Non small cell business |
| Zdroj: | Nat Cancer |
| ISSN: | 2662-1347 |
| Popis: | Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple tumor types, but whether further treatment can improve outcomes in patients with MRD remains unclear. We applied CAPP-Seq ctDNA analysis to 218 samples from 65 patients receiving chemoradiation therapy (CRT) for locally advanced NSCLC, including 28 patients receiving consolidation immune checkpoint inhibition (CICI). Patients with undetectable ctDNA after CRT had excellent outcomes whether or not they received CICI. Among such patients, one died from CICI-related pneumonitis, highlighting the potential utility of only treating patients with MRD. In contrast, patients with MRD after CRT who received CICI had significantly better outcomes than patients who did not receive CICI. Furthermore, the ctDNA response pattern early during CICI identified patients responding to consolidation therapy. Our results suggest that CICI improves outcomes for NSCLC patients with MRD and that ctDNA analysis may facilitate personalization of consolidation therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink